Endocrine Society Members Advocate for Insulin Affordability, Diabetes Prevention, Diabetes Research

The Endocrine Society conducted a Hill Day over April 26, 27, and 28, where we brought together nearly 55 member clinicians, clinical researchers, and basic scientists from 25 states to meet with their Congressional representatives and discuss issues related to diabetes treatment, prevention, and research. Continuing security restrictions on Capitol Hill required that our meetings occur remotely through zoom and other video technologies rather than in person, but, as always, our members were exceptional endocrine advocates and we have already begun to see the impact of our Hill Day.

During these meetings, Society members urged Congress to pass legislation that would make insulin more affordable. Over the past couple of months, we’ve been successful in getting Congress’s attention about this issue. In March, the House voted on legislation that would cap patients’ out-of-pocket insulin costs at $35 per month for people on Medicare and private insurance. Senate leadership indicated that the Senate would consider legislation to address insulin affordability in May, making our Hill Day particularly timely and effective. Our clinician members shared stories with Congressional offices about their patients who have had to forego or ration their prescribed insulin due to cost and, consequently, jeopardized their health and safety. Our members urged Congress to pass insulin affordability legislation that addresses the drivers of rising insulin prices and lowers out-of-pocket costs for people who rely on insulin to manage their diabetes.

Our members urged Congress to pass insulin affordability legislation that addresses the drivers of rising insulin prices and lowers out-of-pocket costs for people who rely on insulin to manage their diabetes.

In addition to discussing insulin affordability, our members made funding requests for the fiscal year 2023 (FY 2023) related to diabetes prevention and research. Our members asked Congress to fully fund the Center for Disease Control and Prevention’s (CDC) National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), the Division of Diabetes Translation (DDT), and the National Diabetes Prevention Program (National DPP). The NCCHPHP funds science-based programs that prevent chronic diseases, including the DDT and National DPP, which are two successful programs that help prevent type 2 diabetes.

On the research front, Society members called on Congress to continue the recent trajectory of steady, sustainable increases in funding for the National Institutes of Health (NIH) by providing the NIH with at least $50 billion in FY 2023. Our NIH-funded members discussed the importance of increased funding for the NIH, and the positive impact that federal funding has on research discoveries in their own districts and states. They also stressed the importance of supporting investigator-initiated research (RO1s) at the NIH.

The Endocrine Society will continue to urge Congress to address insulin affordability and fund diabetes prevention and research in FY 2023. Society members who were unable to participate in our virtual Hill Day, but still want to support insulin affordability, diabetes prevention, and diabetes research can do so by joining our online campaigns at www.endocrine.org/takeaction.

You may also like

  • Biden Continues Focus on ARPA-H, Cancer Moonshot as Francis Collins Takes on New Role

    President Joe Biden has named retired National Institutes of Health director Francis Collins to be the president’s top science adviser until permanent leadership is nominated and confirmed. Eric Lander who formerly led the Office of Science and Technology Programs (OSTP) and held the cabinet-level position of science adviser resigned after it became public that an…

  • Advocacy Victory:  EU Effectively Bans BPA in Food Contact Materials 

    The European Food Safety Administration (EFSA) issued a draft opinion in December that lowers the ‘tolerable daily intake of BPA in food contact materials by six orders of magnitude – effectively a ban on BPA and an advocacy victory for the Endocrine Society. We have called for better regulation of endocrine-disrupting chemicals in food contact materials.    The Endocrine Society will provide supporting comments to…

Find more in